Dihexa vs Cerebrolysin
Comparing synthetic peptide Dihexa with brain-derived peptide mixture Cerebrolysin for cognitive research.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Dihexa
Dossier overview
Cerebrolysin
Dossier overview
Overview
Dihexa and Cerebrolysin represent fundamentally different approaches to potential cognitive enhancement. Dihexa is a synthetic, defined peptide targeting the HGF/c-Met pathway, while Cerebrolysin is a complex mixture of brain-derived peptides. Neither is FDA-approved; Cerebrolysin has some international approvals.
Key Facts
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Type | Synthetic peptide | Brain extract |
| Composition | Single defined molecule | Complex mixture |
| Source | Laboratory synthesis | Porcine brain |
| Mechanism | HGF/c-Met pathway | Neurotrophic (multiple) |
| FDA Status | Not approved | Not approved |
Fundamental Differences
| Characteristic | Dihexa | Cerebrolysin |
|---|---|---|
| Definition | Precisely defined | Complex, variable |
| Mechanism | Specific pathway | Multiple pathways |
| Manufacturing | Chemical synthesis | Biological extraction |
| Reproducibility | High | More variable |
| Characterization | Complete | Partial |
Mechanism Comparison
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Primary Target | HGF/c-Met | Multiple (BDNF-like) |
| Pathway | Specific | Broad |
| Proposed Effect | Synaptogenesis | Neuroprotection |
| Mechanistic Clarity | Higher | Lower |
How They Work
Dihexa:
- Angiotensin IV analog
- Potentiates HGF/c-Met signaling
- Claimed to promote synapse formation
- Very specific mechanism
Cerebrolysin:
- Contains various brain-derived peptides
- BDNF-like activity documented
- Multiple neurotrophic factors
- Broad, undefined mechanism
Evidence Comparison
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Human Trials | None | Multiple |
| Animal Studies | Limited (one group) | Multiple groups |
| Western Publications | Very few | Many |
| Clinical Experience | None | Decades |
Evidence Quality Assessment
Dihexa:
- No human data
- Single research group
- No independent replication
- Extraordinary claims unverified
Cerebrolysin:
- Human trials exist
- Cochrane reviews available
- Mixed but real clinical data
- Used clinically in some regions
Safety Profile
Dihexa Concerns
| Concern | Basis |
|---|---|
| HGF/c-Met and cancer | Pathway promotes tumor growth |
| No human data | Safety completely unknown |
| Potency claims | Concerning if true |
| Quality | Gray market only |
Cerebrolysin Profile
| Aspect | Information |
|---|---|
| Clinical use | Decades of experience |
| Side effects | Documented (injection site, etc.) |
| Serious events | Rare in trials |
| Prion concern | Theoretical (manufacturing controlled) |
Regulatory Status
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| FDA | Not approved | Not approved |
| EU | Not approved | Some countries |
| Russia | Not approved | Approved |
| China | Not approved | Approved |
| Development | Abandoned | Limited Western interest |
Administration
| Aspect | Dihexa | Cerebrolysin |
|---|---|---|
| Route | Oral (claimed), injection | IV or IM |
| Course | Unknown | 10-30 day courses |
| Clinical Protocol | None | Established |
Manufacturing and Quality
| Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Manufacturing | Unknown sources | EU GMP (EVER Pharma) |
| Quality Control | None | Pharmaceutical |
| Batch Consistency | Unknown | Controlled |
| Purity | Unknown | Documented |
Practical Comparison
| Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Evidence for use | None | Weak but exists |
| Safety data | None | Substantial |
| Quality assurance | None | Available |
| Clinical experience | None | Decades |
| Cancer pathway concern | Yes | No |
Risk Assessment
| Risk Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Unknown safety | Very high | Lower |
| Mechanism risk | High (oncogenic) | Low |
| Quality risk | Very high | Low (pharma source) |
| Overall risk level | Very high | Moderate |
Key Differences
| Factor | Dihexa | Cerebrolysin |
|---|---|---|
| Compound type | Defined synthetic | Complex extract |
| Evidence Level | Very low | Moderate |
| Human data | None | Available |
| Safety profile | Unknown | Documented |
| Cancer concern | Yes (HGF/c-Met) | No |
| Quality sources | None | Pharmaceutical |
| Clinical use | Never | Years of use |
Summary
- Dihexa is a synthetic peptide with interesting mechanism but no human data and significant safety concerns (oncogenic pathway)
- Cerebrolysin is a brain-derived mixture with decades of clinical use and documented (though limited) evidence
- Dihexa has no safety profile; Cerebrolysin has extensive clinical experience
- Dihexa’s HGF/c-Met mechanism raises cancer promotion concerns
- Cerebrolysin has pharmaceutical-grade availability; Dihexa does not
- Neither is FDA-approved, but Cerebrolysin has international approvals
- From a risk perspective, Cerebrolysin has known limitations; Dihexa has unknown dangers
This comparison is for educational purposes only. Neither compound is FDA-approved. Dihexa has no human safety data and works through a pathway involved in cancer. Cerebrolysin has clinical experience but insufficient Western evidence. Consult a healthcare provider for medical decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.